Bone mass loss in patients with human immunodeficiency virus type 1 infection: Association with male sex and protease inhibitor therapy

Infectious Diseases in Clinical Practice

Volumn 15, Issue 3, 2007, Pages 160-166

  Calza, Leonardo ^a   Tampellini, Livia ^a   Farneti, Barbara ^a   Borderi, Marco ^a   Chiara Pajno, Maria ^a   Biagetti, Carlo ^a   Manfredi, Roberto ^a   Vescini, Fabio ^a   Caudarella, Renata ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR HEAD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; SCORING SYSTEM; SEX DIFFERENCE;

EID: 34249000774     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000269907.56982.a5     Document Type: Article

References (38)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F52.
2. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:25-32.
3. Rietshel P, Corcoran C, Stanley T, et al. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis. 2000;31:1240-1244.
4. Calza L, Manfredi R, Chiodo F. Subclinical hypothyroidism in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:361-363.
5. Quero JH, Centeno NO, Munoz-Torres M. Alterations in bone turnover in HIV-positive patients. Infection. 1993;21:220-222.
6. Serrano S, Marinoso ML, Soriano JC, et al. Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone. 1995;16:185-191.
7. Mellert W, Kleinschmidt A, Schmidt J, et al. Infection of human fibroblasts and osteoblast-like cells with HIV-1. AIDS. 1990;4:527-535.
8. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63-F67.
9. Hoy J, Hudson J, Law M, et al. Osteopenia in a randomized, multicenter study of protease inhibitor (PI) substitution in patients with lipodystrophy syndrome and well controlled HIV viremia [abstract 59]. Paper presented at: 7th Conference on Retroviruses and Opportunistic Infections; February 2000; San Francisco, CA.
10. Moore A, Vashisht A, Sabin CA, et al. Reduced bone density in HIV-positive individuals. AIDS. 2001;15:1731-1733.
11. Madeddu G, Spanu A, Solinas P. Bone mass loss risk in HIV-infected patients treated with highly active antiretroviral therapy including protease inhibitors. Antiviral Ther. 2001;6(suppl 4):56.
12. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral loss in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001;15:1275-1280.
13. Aukrust P, Huag CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodelling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999;84:145-150.
14. Looker AC, Orwoll ES, Johnston CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761-1768.
15. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser. 1994;843:1-129.
16. Landonio S, Quirino T, Bonfanti P, et al. Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART. Biomed Pharmacother. 2004;58:505-508.
17. McGowan I, Cheng A, Coleman S. Assessment of bone mineral density (BMD) in HIV-infected antiretroviral therapy-naive patients [abstract 628]. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 2001; Chicago, IL.
18. Knobel H, Guelar A, Vallecillo G, et al. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS. 2001;15:807-808.
19. Lawal A, Engelson ES, Wang J, et al. Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS. 2001;15:278-280.
20. Huang JS, Rietschel P, Hadigan CM, et al. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS. 2001;15:975-982.
21. Mora S, Sala N, Bricalli D, et al. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS. 2001;15:1823-1829.
22. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48:39-48.
23. Carr A, Miller J, Eisman JA, et al. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight preantiretroviral therapy. AIDS. 2001;15:703-709.
24. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-490.
25. Paton NI, Macallan DC, Griffin GE, et al. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int. 1997;61:30-32.
26. Nacher M, Serrano S, Gonzales A, et al. Osteoblast in HIV-infected patients: HIV-1 infection and cell function. AIDS. 2001;15:2239-2243.
27. Aukrust P, Liabakk NB, Muller F, et al. Serum levels of tumor necrosis factor (TNF)-alpha and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virologic parameters. J Infect Dis. 1994;169:420-424.
28. Roodman GD. Role of cytokines in the regulation of bone resorption. Calcif Tissue Int. 1993;53(suppl 1):S94-S98.
29. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res. 1996;11:1043-1051.
30. Seminari E, Castagna A, Soldarini A, et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med. 2005;6:145-150.
31. Caron M, Auclair M, Kornprobst M, et al. Indinavir-induced nuclear lamina alterations are correlated with adipocyte dysfunction in cultured adipocytes. Antiviral Ther. 2002;7(suppl 3):L1.
32. Wang MW, Wei S, Faccio R, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest. 2004;114:206-213.
33. Pan G, Wu X, McKenna MA, et al. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses. 2004;20:608-620.
34. Cozzolino M, Vidal M, Arcidiacono MV, et al. HIV protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17:513-520.
35. Haug CJ, Aukrust P, Haug E, et al. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83:3832-3838.
36. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials. 2004;5:269-277.
37. Mondy K, Powderly WG, Claxon SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38:426-431.
38. Negredo E, Martinez-Lopez E, Paredes R, et al. Reversal AIDS. 2005;19:343-345.